Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Q3 2025 value amounting to $72.4 million.

  • Syndax Pharmaceuticals' Cash from Investing Activities fell 1660.16% to $72.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.5 million, marking a year-over-year decrease of 28389.15%. This contributed to the annual value of -$219.8 million for FY2024, which is 28686.92% down from last year.
  • As of Q3 2025, Syndax Pharmaceuticals' Cash from Investing Activities stood at $72.4 million, which was down 1660.16% from $41.9 million recorded in Q2 2025.
  • In the past 5 years, Syndax Pharmaceuticals' Cash from Investing Activities registered a high of $94.1 million during Q1 2025, and its lowest value of -$269.0 million during Q4 2024.
  • Moreover, its 5-year median value for Cash from Investing Activities was $19.9 million (2023), whereas its average is -$6.4 million.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Cash from Investing Activities skyrocketed by 68997.5% in 2023, and later plummeted by 155115.41% in 2024.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Cash from Investing Activities stood at -$60.0 million in 2021, then tumbled by 129.55% to -$137.6 million in 2022, then surged by 88.16% to -$16.3 million in 2023, then crashed by 1551.15% to -$269.0 million in 2024, then skyrocketed by 126.93% to $72.4 million in 2025.
  • Its Cash from Investing Activities was $72.4 million in Q3 2025, compared to $41.9 million in Q2 2025 and $94.1 million in Q1 2025.